SITC Announces Keynote Speaker Dr. Ignacio Melero at the Immuno-oncology Drug Development Summit
Summary
"SITC is excited to gather leaders from diverse sectors of the drug development ecosystem, including biotech, pharma, academia, government, and finance, to discuss bringing new cancer therapeutics to patients in a more rapid fashion," remarked Leisha A. Emens, MD, PhD, President of SITC. Additional day two content includes investor perspectives on chimeric antigen receptors, AI and immune cell engagers. "This has required active collaboration between patients, academia, the pharma/biotech ecosystem, regulatory agencies and investors to realize this progress. View the entire schedule of expert speakers and session topics at the SITC IO Drug Development web page. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word "cure" a reality for cancer patients everywhere.